[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]
Pricing protest at Hoffman LaRoche booth in Vancouver
- To: email@example.com
- Subject: Pricing protest at Hoffman LaRoche booth in Vancouver
- From: "JOHN-HENERY RILEY" <firstname.lastname@example.org>
- Date: Mon, 12 Aug 1996 11:01:05 EST
- Priority: normal
- Return-Receipt-To: "JOHN-HENERY RILEY" <email@example.com>
Day 4 ACT UP AWARDS GOLDEN URN TO:
Fifty members of ACT UP from around the globe chanting, carrying signs
and carrying the Golden (funeral) Urn descended upon the ostentatious
booth of Hoffman LaRoche. (ACT UP gave out Golden Urns to drug companies,
public officials, and organizations whose policies and actions are hastening
the deaths of people with AIDS.)Activists plastered the booth with stickers
reading "AIDS Profiteer" and "Greed equals Death" . Activist also left
"La Roach motels" in and around the booth. This is the text of the
ACT UP AWARDS GOLDEN URN TO:
for killer pricing policies and indifference to AIDS.
We are presenting another Golden Urn award to Hoffman "the Roach" for
their long tradition of placing corporate greed above the lives of
people living with AIDS. The obscene price of their new protease
inhibitor, Invirase, is one more link in a never-ending chain of
In the United States, their prices for Invirase and Hivid (Roche's
nucleoside analog) are bankrupting government programs which provide
drugs to low- and moderate-income people living with AIDS.
Roche was the first company to sell a protease inhibitor, and the
price they chose ($7,2000 annually) set the standard for the market.
The company demands this high price even though they admit that
Invirase is poorly-absorbed and under-dosed in its current form. Roche
has refused repeated requests by activists to justify its price by
allowing a confidential independent review of its actual research and
Roche also displayed contempt for seriously-ill people living with
AIDS by delaying its compassionate release program for so long that
Invirase was fully-approved before the program was up and running.
Consequently, many of those slated to receive free Invirase in this
manner ended up being charged for it.
Roche has also turned its back on teen-agers living with HIV/AIDS be
refusing to lower the age limit of the clinical trials to 13 years,
as other companies have done.
Adolescents' bodies absorb drugs similarly to adults so there is no
reason to exclude them from studies which would provide important
data, as well as providing young people access to their drugs. Roche
has also dragged its feet on important pediatric studies of its
products, such as Invirase.
To see photo's of this action and others during the week of the
international AIDS Conference in Vancouver go the ACT UP/NY's web site
at : www.actupny.org.